NanoViricides, Inc. (NNVC)
1.14
-0.03
(-2.56%)
USD |
NYAM |
Nov 20, 16:00
1.14
0.00 (0.00%)
After-Hours: 20:00
NanoViricides Debt to Equity Ratio : 0.00 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.00 |
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.0011 |
| June 30, 2022 | 0.0041 |
| March 31, 2022 | 0.0067 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.0008 |
| June 30, 2021 | 0.0032 |
| March 31, 2021 | 0.0052 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.0369 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.0526 |
| March 31, 2020 | 0.0825 |
| December 31, 2019 | 0.1376 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.2265 |
| June 30, 2017 | 0.1947 |
| March 31, 2017 | 0.1666 |
| December 31, 2016 | 0.4928 |
| September 30, 2016 | 0.4456 |
| June 30, 2016 | 0.3735 |
| March 31, 2016 | 0.3431 |
| December 31, 2015 | 0.2771 |
| September 30, 2015 | 0.2552 |
| June 30, 2015 | 0.3608 |
| March 31, 2015 | 0.2701 |
| December 31, 2014 | 0.3622 |
| September 30, 2014 | 0.2078 |
| June 30, 2014 | 0.8547 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2815 |
| Arrowhead Pharmaceuticals, Inc. | 27.84 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 9.563M |
| Total Liabilities (Quarterly) | 3.150M |
| Shareholders Equity (Quarterly) | 6.412M |
| Current Ratio | 0.946 |